Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Medical Center Goettingen
About this trial
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
Eligibility criteria
Qualifiers
Age > 60 years
Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs)
Diabetes mellitus Type I or II
Atrial fibrillation
Disqualifiers
Left ventricular ejection fraction < 50 %
Significant valve disease (Grade III or higher)
History of interventional or surgical valve repair
Regional wall motion abnormalities
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Universitätsmedizin Göttingen37075, GöttingenLower Saxony, Germany
Sponsors and collaborators
University Medical Center Goettingen
Lead sponsor
Source ClinicalTrials.gov